Roche's TIG­IT win lim­it­ed by stan­dard of care change, lack of glob­al study

Roche’s TIG­IT an­ti­body tiragolum­ab fi­nal­ly scored a Phase III win fol­low­ing two con­sec­u­tive late-stage fails last year, thanks to its SKY­SCRAPER-08 tri­al com­par­ing its TIG­IT …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER